Open Access Could Transform Drug Discovery: A Case Study of JQ1

Expert Opinion on Drug Discovery
Zeeshaan ArshadDavid Brindley

Abstract

The cost to develop a new drug from target discovery to market is a staggering $1.8 billion, largely due to the very high attrition rate of drug candidates and the lengthy transition times during development. Open access is an emerging model of open innovation that places no restriction on the use of information and has the potential to accelerate the development of new drugs. To date, no quantitative assessment has yet taken place to determine the effects and viability of open access on the process of drug translation. This need is addressed within this study. The literature and intellectual property landscapes of the drug candidate JQ1, which was made available on an open access basis when discovered, and conventionally developed equivalents that were not are compared using the Web of Science and Thomson Innovation software, respectively. Results demonstrate that openly sharing the JQ1 molecule led to a greater uptake by a wider and more multi-disciplinary research community. A comparative analysis of the patent landscapes for each candidate also found that the broader scientific diaspora of the publically released JQ1 data enhanced innovation, evidenced by a greater number of downstream patents filed in relation to JQ1. The ...Continue Reading

References

Sep 1, 1991·Archives of Environmental Health·K Emmons, W M Foster
May 23, 1998·Science·M A Heller, R S Eisenberg
Oct 11, 2001·Public Health·F Sim, P Mackie
Jun 19, 2002·Alzheimer Disease and Associated Disorders·Ravi Anand
Jul 18, 2002·Nature Reviews. Drug Discovery·Renaud CapdevilleAlex Matter
Jan 17, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P W ManleyJ Zimmermann
Mar 9, 2004·Health Affairs·Iain M Cockburn
Apr 3, 2004·Nature Reviews. Drug Discovery·Michael D Rawlins
Aug 3, 2004·Nature Reviews. Drug Discovery·Ismail Kola, John Landis
Feb 3, 2005·Nature Reviews. Drug Discovery·Fredric J Cohen
Apr 27, 2005·Chemical Society Reviews·Darren B Hansen, Madeleine M Joullie
Aug 18, 2006·Nature Reviews. Drug Discovery·Bernard Munos
Aug 30, 2008·Therapeutics and Clinical Risk Management·Omar S Din, Penella J Woll
May 1, 2009·Nature Reviews. Drug Discovery
Jun 19, 2009·Nature Chemical Biology·Aled M EdwardsTimothy M Willson
Dec 2, 2009·Nature Reviews. Drug Discovery·Bernard Munos
Feb 20, 2010·Nature Reviews. Drug Discovery·Steven M PaulAaron L Schacht
Sep 28, 2010·Nature·Panagis FilippakopoulosJames E Bradner
Jan 5, 2011·Nature Reviews. Drug Discovery·Charlotte Harrison
Jan 12, 2011·Nature Biotechnology·Mark Kessel
Apr 22, 2011·Toxicological Sciences : an Official Journal of the Society of Toxicology·James H Kim, Anthony R Scialli
May 19, 2011·Nature Chemical Biology·Mark E Bunnage
Jul 1, 2011·Science Translational Medicine·Bernard H Munos, William W Chin
Aug 2, 2011·Nature Reviews. Drug Discovery·John L LaMattina
Jan 20, 2012·Nature·David BrindleyChris Mason
Feb 7, 2012·Lancet·Christopher J L MurrayAlan D Lopez
Mar 2, 2012·Nature Reviews. Drug Discovery·Jack W ScannellBrian Warrington
Jun 20, 2012·Proceedings of the National Academy of Sciences of the United States of America·Elisabet Gregori-PuigjanéBrian K Shoichet
Oct 2, 2012·Nature Biotechnology·Jose-Maria FernandezAndrew W Lo
Oct 19, 2012·The New England Journal of Medicine·Jeremy A Greene, Scott H Podolsky
Nov 6, 2012·Nature Reviews. Drug Discovery·Anne CorbettClive Ballard
Dec 1, 2012·Nature Reviews. Drug Discovery·Joanne BowesSteven Whitebread
Mar 30, 2013·Science·Andrew QuigleyElisabeth P Carpenter
Jun 19, 2013·Drug Discovery Today·Gemma K LambertManoj K Ramjee
Jun 27, 2013·PloS One·Thomas SpangenbergPaul Willis
Jul 16, 2014·Alzheimer's Research & Therapy·Jeffrey L CummingsKate Zhong
Aug 6, 2014·Nature Biotechnology·MacKenna RobertsDavid A Brindley
Aug 13, 2014·Current Opinion in Pharmacology·Stefan Knapp, Michael Sundström
Sep 5, 2014·Science Translational Medicine·Nathan P StaffAnthony J Windebank
Jun 20, 2015·Nature Reviews. Drug Discovery·Michael J WaringAlex Weir

❮ Previous
Next ❯

Citations

May 12, 2016·Nature·Andrew R Scott
Mar 8, 2017·Nature Biotechnology·James A SmithDavid A Brindley
Jul 10, 2019·Expert Opinion on Drug Discovery·Paul WorkmanBissan Al-Lazikani
Feb 23, 2018·Frontiers in Neuroscience·Chanshuai HanThomas M Durcan
Apr 19, 2019·PeerJ·Joseph D TuckerBarry Bayus
Feb 2, 2019·Wellcome Open Research·Maxwell Robert MorganAled Morgan Edwards
Oct 31, 2020·Future Medicinal Chemistry·Kyle E MurphyAmanda L Wolfe
Feb 2, 2021·Frontiers in Pharmacology·Andy Wai Kan YeungEva Schaden
Aug 31, 2021·RSC Chemical Biology·Robert B A Quinlan, Paul E Brennan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.